Do testosterone and sex hormone-binding globulin affect cancer risk? A Mendelian randomization and bioinformatics study

References

• Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–3030. doi: 10.1002/cncr.33587.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771–1779. doi: 10.2217/fon.10.127.
   PubMed Web of Science ®Google Scholar
• Yin Z, Su M, Li X, et al. ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in chinese non-smoking females. J Exp Clin Cancer Res. 2009;28(1):153. doi: 10.1186/1756-9966-28-153.
   PubMedGoogle Scholar
• Durdiakova J, Ostatnikova D, Celec P. Testosterone and its metabolites–modulators of brain functions. Acta Neurobiologiae Experimentalis. 2011;71(4):434–454.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the testosterone trials. Endocr Rev. 2018;39(3):369–386. doi: 10.1210/er.2017-00234.
   PubMed Web of Science ®Google Scholar
• Glaser R, Dimitrakakis C. Testosterone and breast cancer prevention. Maturitas. 2015;82(3):291–295. doi: 10.1016/j.maturitas.2015.06.002.
   PubMed Web of Science ®Google Scholar
• Ørsted DD, Nordestgaard BG, Bojesen SE. Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study. Ann Oncol. 2014;25(3):712–718. doi: 10.1093/annonc/mdt590.
   PubMed Web of Science ®Google Scholar
• Fourkala EO, Zaikin A, Burnell M, et al. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocr Relat Cancer. 2012;19(2):137–147. doi: 10.1530/ERC-11-0310.
   PubMed Web of Science ®Google Scholar
• Trabert B, Michels KA, Anderson GL, et al. Circulating androgens and postmenopausal ovarian cancer risk in the women’s health initiative observational study. Int J Cancer. 2019;145(8):2051–2060. doi: 10.1002/ijc.32157.
   PubMed Web of Science ®Google Scholar
• Khosla S. Editorial: sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid action? J Clin Endocrinol Metab. 2006;91(12):4764–4766. doi: 10.1210/jc.2006-1990.
   PubMed Web of Science ®Google Scholar
• Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53(1):58–68. doi: 10.1210/jcem-53-1-58.
   PubMed Web of Science ®Google Scholar
• Fortunati N, Catalano MG. Sex hormone-binding globulin (SHBG) and estradiol cross-talk in breast cancer cells. Horm Metab Res. 2006;38(4):236–240. doi: 10.1055/s-2006-925337.
   PubMed Web of Science ®Google Scholar
• Zhu JL, Chen Z, Feng WJ, et al. Sex hormone-binding globulin and polycystic ovary syndrome. Clin Chim Acta. 2019;499:142–148. doi: 10.1016/j.cca.2019.09.010.
   PubMed Web of Science ®Google Scholar
• Hyde Z, Flicker L, McCaul KA, et al. Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1319–1329. doi: 10.1158/1055-9965.EPI-12-0129.
   PubMed Web of Science ®Google Scholar
• Dimou NL, Papadimitriou N, Gill D, et al. Sex hormone binding globulin and risk of breast cancer: a Mendelian randomization study. Int J Epidemiol. 2019;48(3):807–816. doi: 10.1093/ije/dyz107.
   PubMed Web of Science ®Google Scholar
• Ruth KS, Day FR, Tyrrell J, et al. Using human genetics to understand the disease impacts of testosterone in men and women. Nat Med. 2020;26(2):252–258. doi: 10.1038/s41591-020-0751-5.
   PubMed Web of Science ®Google Scholar
• Murphy N, Strickler HD, Stanczyk FZ, et al. A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women. J Natl Cancer Inst. 2015;107(10):djv210.
   Google Scholar
• Burgess S, Scott RA, Timpson NJ, et al. Using published data in mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol. 2015;30(7):543–552. doi: 10.1007/s10654-015-0011-z.
   PubMed Web of Science ®Google Scholar
• Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013;178(7):1177–1184. doi: 10.1093/aje/kwt084.
   PubMed Web of Science ®Google Scholar
• Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133–1163. doi: 10.1002/sim.3034.
   PubMed Web of Science ®Google Scholar
• Bochud M, Rousson V. Usefulness of Mendelian randomization in observational epidemiology. Int J Environ Res Public Health. 2010;7(3):711–728. doi: 10.3390/ijerph7030711.
   PubMed Web of Science ®Google Scholar
• Gene Ontology. C. Gene ontology consortium: going forward. Nucleic Acids Res. 2015;43(Database issue):D1049–56.
   PubMedGoogle Scholar
• Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. doi: 10.1093/nar/28.1.27.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi: 10.1089/omi.2011.0118.
   PubMed Web of Science ®Google Scholar
• Phelan CM, Kuchenbaecker KB, Tyrer JP, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017;49(5):680–691. doi: 10.1038/ng.3826.
   PubMed Web of Science ®Google Scholar
• Wang Y, McKay JD, Rafnar T, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014;46(7):736–741. doi: 10.1038/ng.3002.
   PubMed Web of Science ®Google Scholar
• Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer. 2004;104:636–642. doi:10.1002/ijc.11529.
   Google Scholar
• Arthur RS, Dannenberg AJ, Rohan TE. The association of prediagnostic circulating levels of cardiometabolic markers, testosterone and sex hormone-binding globulin with risk of breast cancer among normal weight postmenopausal women in the UK Biobank. Int J Cancer. 2021;149(1):42–57. doi: 10.1002/ijc.33508.
   PubMed Web of Science ®Google Scholar
• Nounu A, Kar SP, Relton CL, et al. Sex steroid hormones and risk of breast cancer: a two-sample mendelian randomization study. Breast Cancer Res. 2022;24(1):66. doi: 10.1186/s13058-022-01553-9.
   PubMed Web of Science ®Google Scholar
• Tang SN, Zuber V, Tsilidis KK. Identifying and ranking causal biochemical biomarkers for breast cancer: a Mendelian randomisation study. BMC Med. 2022;20(1):457. doi: 10.1186/s12916-022-02660-2.
   PubMed Web of Science ®Google Scholar
• Frasor J, Danes JM, Komm B, et al. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology. 2003;144(10):4562–4574. doi: 10.1210/en.2003-0567.
   PubMed Web of Science ®Google Scholar
• Lukanova A, Lundin E, Akhmedkhanov A, et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer. 2003;104(5):636–642. doi: 10.1002/ijc.10990.
   PubMed Web of Science ®Google Scholar
• Tworoger SS, Lee IM, Buring JE, et al. Plasma androgen concentrations and risk of incident ovarian cancer. Am J Epidemiol. 2008;167(2):211–218. doi: 10.1093/aje/kwm278.
   PubMed Web of Science ®Google Scholar
• Schock H, Surcel HM, Zeleniuch-Jacquotte A, et al. Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer. Endocr Relat Cancer. 2014;21(6):831–844. doi: 10.1530/ERC-14-0282.
   PubMed Web of Science ®Google Scholar
• Ose J, Fortner RT, Rinaldi S, et al. Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European prospective investigation into cancer and nutrition. Int J Cancer. 2015;136(2):399–410. doi: 10.1002/ijc.29000.
   PubMed Web of Science ®Google Scholar
• Trabert B, Brinton LA, Anderson GL, et al. Circulating estrogens and postmenopausal ovarian cancer risk in the women’s health initiative observational study. Cancer Epidemiol Biomarkers Prev. 2016;25(4):648–656. doi: 10.1158/1055-9965.EPI-15-1272-T.
   PubMed Web of Science ®Google Scholar
• Ose J, Poole EM, Schock H, et al. Androgens are differentially associated with ovarian cancer subtypes in the ovarian cancer cohort consortium. Cancer Res. 2017;77(14):3951–3960. doi: 10.1158/0008-5472.CAN-16-3322.
   PubMed Web of Science ®Google Scholar
• Modugno F, Laskey R, Smith AL, et al. Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer. 2012;19(6):R255–79. doi: 10.1530/ERC-12-0175.
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Plummer M, Biessy C, et al. Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2532–2540. doi: 10.1158/1055-9965.EPI-11-0753.
   PubMed Web of Science ®Google Scholar
• Everhov ÅH, Flöter Rådestad A, Nyberg T, et al. Serum androgen levels and sexual function before and one year after treatment of uterine cervical cancer: a pilot study. J Sex Med. 2016;13(3):413–424. doi: 10.1016/j.jsxm.2015.12.022.
   PubMed Web of Science ®Google Scholar
• Wallin E, Falconer H, Rådestad AF. Sexual, bladder, bowel and ovarian function 1 year after robot-assisted radical hysterectomy for early-stage cervical cancer. Acta Obstet Gynecol Scand. 2019;98(11):1404–1412. doi: 10.1111/aogs.13680.
   PubMed Web of Science ®Google Scholar
• Shields TS, Falk RT, Herrero R, et al. A case-control study of endogenous hormones and cervical cancer. Br J Cancer. 2004;90(1):146–152. doi: 10.1038/sj.bjc.6601514.
   PubMed Web of Science ®Google Scholar
• Guo WD, Hsing AW, Li JY, et al. Correlation of cervical cancer mortality with reproductive and dietary factors, and serum markers in China. Int J Epidemiol. 1994;23(6):1127–1132. doi: 10.1093/ije/23.6.1127.
   PubMed Web of Science ®Google Scholar
• Mc Menamin ÚC, Kunzmann AT, Cook MB, et al. Hormonal and reproductive factors and risk of upper gastrointestinal cancers in men: a prospective cohort study within the UK Biobank. Int J Cancer. 2018;143(4):831–841. doi: 10.1002/ijc.31375.
   PubMed Web of Science ®Google Scholar
• Chang J, Wu Y, Zhou S, et al. Genetically predicted testosterone and cancers risk in men: a two-sample Mendelian randomization study. J Transl Med. 2022;20(1):573. doi: 10.1186/s12967-022-03783-z.
   PubMed Web of Science ®Google Scholar
• Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88(16):1118–1126. doi: 10.1093/jnci/88.16.1118.
   PubMedGoogle Scholar
• Watts EL, Perez-Cornago A, Fensom GK, et al. Circulating free testosterone and risk of aggressive prostate cancer: prospective and Mendelian randomisation analyses in international consortia. Int J Cancer. 2022;151(7):1033–1046. doi: 10.1002/ijc.34116.
   PubMed Web of Science ®Google Scholar
• García-Cruz E, Carrión Puig A, García-Larrosa A, et al. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy. Scand J Urol. 2013;47(4):282–289. doi: 10.3109/00365599.2012.747562.
   PubMed Web of Science ®Google Scholar
• Andersson SO, Adami HO, Bergström R, et al. Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer–a population-based case-control study. Br J Cancer. 1993;68(1):97–102. doi: 10.1038/bjc.1993.293.
   PubMed Web of Science ®Google Scholar
• Tsilidis KK, Travis RC, Appleby PN, et al. Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the national cancer institute breast and prostate cancer cohort consortium. Am J Epidemiol. 2012;175(9):926–935. doi: 10.1093/aje/kwr423.
   PubMed Web of Science ®Google Scholar
• Chen F, Wen W, Long J, et al. Mendelian randomization analyses of 23 known and suspected risk factors and biomarkers for breast cancer overall and by molecular subtypes. Int J Cancer. 2022;151(3):372–380. doi: 10.1002/ijc.34026.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zheng Z, Zhang F, et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat Commun. 2018;9(1):224. doi: 10.1038/s41467-017-02317-2.
   PubMedGoogle Scholar
• Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol. 2017;14(10):577–590. doi: 10.1038/nrcardio.2017.78.
   PubMed Web of Science ®Google Scholar